Axogen, Inc. (AXGN) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-05-08

Key Insights

Sales VP Doris Quackenbush sold 3,878 shares of AXGN on 05/07/2026 at a weighted average price of $43.507, reducing her direct ownership from approximately 96,294 shares to 92,416 shares.
The sale was executed across multiple transactions within a narrow price range ($43.50-$44.00), suggesting a planned, deliberate disposition rather than panic selling, which is typical for officers managing their portfolio.
Following this transaction, Quackenbush retains a substantial direct shareholding of 92,416 shares, indicating continued confidence in the company despite the partial liquidation.

Want the newest filings?

This analysis covers the filing from 2026-05-08. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-05-08

CFO Lindsey Hartley exercised 5,463 stock options on 05/07/2026 at strike prices of $8.20 and $8.27, indicating confidence in the company's near-term prospects given the current stock price of $43.67.
Immediately following option exercises, the insider sold 1,051 shares at $43.67, netting approximately $45,900 in proceeds—a classic sell-to-cover pattern to fund tax obligations from option exercises rather than signaling loss of confidence.
The two separate option grants show different vesting schedules, with the 2,500-share tranche fully vested as of March 2026 and the 2,963-share tranche on a 4-year schedule with 50% cliff vesting—typical equity compensation structure for CFO-level executives.
Post-transaction beneficial ownership stands at approximately 65,146 shares held directly, representing a modest net increase despite the sell activity, suggesting the insider is maintaining substantial equity exposure to the company.

Filed: 2026-05-08

Chief Marketing Officer Jens Kemp sold 4,000 shares of AXGN on 05/07/2026 at a weighted average price of $43.44, reducing his direct beneficial ownership from approximately 76,451 to 72,451 shares.
The sale was executed through multiple transactions within a narrow price range ($43.44-$43.45), suggesting a planned or systematic disposition rather than opportunistic selling at market fluctuations.
As a C-suite executive (CMO), this insider sale could indicate either portfolio rebalancing or potential concerns about near-term company prospects, though the modest sale size (4,000 shares) suggests routine position management rather than significant confidence loss.
The officer retains substantial direct ownership of 72,451 shares post-transaction, indicating continued meaningful financial alignment with the company's performance.

Filed: 2026-05-08

Director Kathy Weiler executed a same-day exercise-and-sell transaction, exercising 16,344 stock options at $6.95 and immediately selling all shares at an average price of $44.09, suggesting confidence in current valuation but no conviction to hold.
The significant spread between exercise price ($6.95) and sale price ($44.09) represents a ~535% gain, indicating substantial stock appreciation since the options were granted, though the immediate liquidation limits insider confidence signals.
Weiler received 16,344 options as a board director grant vesting over three years starting December 2024, with 27,307 options remaining in her beneficial ownership, showing ongoing equity incentive alignment with the company.

Filed: 2026-05-08

Director John Johnson exercised 11,050 stock options at $7.04 per share on 05/07/2026, immediately selling all shares at a weighted average price of $43.255, realizing a gain of approximately $399,000 or 515% return
The immediate sale of all exercised shares (same-day exercise and sell-off) suggests opportunistic profit-taking rather than confidence in future stock appreciation, which is a neutral to slightly negative signal
Johnson's options were fully vested as of June 6, 2025, indicating this was a planned transaction executing a vested position rather than an unexpected or emergency sale

Filed: 2026-03-18

Lindsey Hartley, the CFO of Axogen Inc. (AXGN), exercised 9,000 restricted stock units (RSUs) on March 16, 2026, with 4,000 shares vesting and 5,000 shares vesting.
Hartley sold 3,542 shares to cover tax withholding obligations, indicating a partial liquidation of her equity holdings.
Hartley's remaining direct ownership stands at 60,734 shares, suggesting she continues to maintain a significant stake in the company.

Filed: 2026-03-18

The reporting person, Erick DeVinney, is the Chief Innovation Officer of Axogen, Inc. and has acquired and disposed of common stock through the vesting and net settlement of restricted stock units.
DeVinney has acquired a total of 17,938 shares of common stock through the vesting of restricted stock units, and has sold 5,221 shares to cover tax withholding obligations.
The total number of shares beneficially owned by DeVinney following the reported transactions is 262,781 shares of Axogen, Inc. common stock.

Filed: 2026-02-27

Michael D. Dale, the Chief Executive Officer of Axogen, Inc., has been granted 98,000 restricted stock units (RSUs) that will vest over a 4-year period.
The RSUs are intended to provide long-term incentives and align the CEO's interests with those of Axogen's shareholders.
The vesting schedule indicates that the CEO's equity ownership in the company will increase gradually, with 50% of the shares vesting after 2 years and the remaining 50% vesting in the following 2 years.

Filed: 2026-02-27

The reporting person, Lindsey Hartley, acquired 17,453 shares of Axogen, Inc. common stock on February 26, 2026, likely through the vesting of performance-based restricted stock units.
Hartley also had 6,630 shares withheld by the company to satisfy tax obligations, indicating a net increase in her direct ownership of Axogen shares.
Hartley was granted an additional 23,000 restricted stock units, which will vest over the next 4 years, further aligning her interests with those of Axogen shareholders.

Filed: 2026-02-24

Lindsey Hartley, the CFO of Axogen Inc., acquired 17,500 shares of the company's common stock on February 22, 2026, indicating continued confidence in the company's future prospects.
The reporting person also had 6,704 shares withheld by the issuer to cover tax withholding obligations upon the vesting of restricted stock units, suggesting a potential long-term focus on the company's performance.
The total number of shares beneficially owned by the CFO following the reported transaction is 44,453, demonstrating a significant personal investment in the company.

Other reports for Axogen, Inc.

Current Report Quarterly Report Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.